Thomas Wayne Gibbs

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in

GenePOC, Inc. develops rapid molecular devices to detect genes at point-of-care. Its product includes an integrated portable instrument for the prevention and early detection of infectious diseases based on a centripetal technology platform. Its product also includes GenePOC disposable, a device for performing nucleic acid-based diagnostics at POC. The company’s products are also used for infectious disease, rapid food microbiology, and human pharmacogenetic testing applications. The company was founded by Michel G. Bergeron in 2007 and is headquartered in Quebec, Canada.

Med Discovery SA is a Swiss biopharmaceutical company that develops treatments for cancers. The private company was founded by David Luc Deperthes.

Covalys Biosciences AG develops and produces tools for protein research. The company was founded by Patrik Siedler, Maik Kindermann, Christoph Bieri, Henri Zinsli and Nils Johnsson in June 2002 and is headquartered in Witterswil, Switzerland.

Diagnoplex SA develops molecular diagnostics for colon cancer. It lead product, Colox is a minimally-invasive blood test developed for the systematic screening and detection of early and advanced colorectal cancer. The company was founded in April 2005 by Stavros Therianos, Curzio Roberto Maria Rüegg, Jacques R. Essinger and Jean-Pierre Rosat and is headquartered in Lausanne, Switzerland.

Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA.